본문 바로가기
KERD
논문KCI 등재

An Overview of Human Immunodeficiency Virus-1 Antiretroviral Drugs: General Principles and Current Status

Yoon Cheol-Hee|Shin Young Hyun|Park Chul Min
대한감염학회 (The Korean Society Of Infectious Diseases)|2021.03|Infection and Chemotherapy|제53권 제1호|pp. 29-45|DOI 10.3947/ic.2020.0100

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

Human immunodeficiency virusHIV-1 TatAnti-HIV-1 drugs
주제분류내과학

초록

Treatment with highly active antiretroviral therapy (HAART) can prolong a patient's life-span by disrupting pivotal steps in the replication cycle of the human immunodeficiency virus-1 (HIV-1). However, drug resistance is emerging as a major problem worldwide due to the prolonged period of treatment undergone by HIV-1 patients. Since the approval of zidovudine in 1987, over thirty antiretroviral drugs have been categorized into the following six distinct classes based on their biological function and resistance profiles: (1) nucleoside analog reverse-transcriptase inhibitors; (2) non–nucleoside reverse transcriptase inhibitors; (3) integrase strand transferase inhibitors; (4) protease inhibitors; (5) fusion inhibitors; and (6) co-receptor antagonists. Additionally, several antiretroviral drugs have been developed recently, such as a long active drug, humanized antibody and pro-drug metabolized into an active form in the patient's body. Although plenty of antiretroviral drugs are beneficially used to treat patients with HIV-1, the ongoing efforts to develop antiretroviral drugs have overcome the drug resistances, adverse effects, and limited adherence of drugs observed in previous drugs to some extent. Furthermore, studies focused on agents targeting latent HIV-1 reservoirs should be strengthened, as that may lead to eradication of HIV-1.

Abstract

Treatment with highly active antiretroviral therapy (HAART) can prolong a patient's life-span by disrupting pivotal steps in the replication cycle of the human immunodeficiency virus-1 (HIV-1). However, drug resistance is emerging as a major problem worldwide due to the prolonged period of treatment undergone by HIV-1 patients. Since the approval of zidovudine in 1987, over thirty antiretroviral drugs have been categorized into the following six distinct classes based on their biological function and resistance profiles: (1) nucleoside analog reverse-transcriptase inhibitors; (2) non–nucleoside reverse transcriptase inhibitors; (3) integrase strand transferase inhibitors; (4) protease inhibitors; (5) fusion inhibitors; and (6) co-receptor antagonists. Additionally, several antiretroviral drugs have been developed recently, such as a long active drug, humanized antibody and pro-drug metabolized into an active form in the patient's body. Although plenty of antiretroviral drugs are beneficially used to treat patients with HIV-1, the ongoing efforts to develop antiretroviral drugs have overcome the drug resistances, adverse effects, and limited adherence of drugs observed in previous drugs to some extent. Furthermore, studies focused on agents targeting latent HIV-1 reservoirs should be strengthened, as that may lead to eradication of HIV-1.

참고문헌 (91)

  1. Barré-Sinoussi F, "Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)", Science, 220, pp.868~871 (1983)
  2. Gallo RC, "The discovery of HIV as the cause of AIDS", N Engl J Med, 349, pp.2283~2285 (2003)
  3. Gallo RC, "HIV-1: a look back from 20 years", DNA Cell Biol, 23, pp.191~192 (2004)
  4. Weiss RA, "How does HIV cause AIDS", Science, 260, pp.1273~1279 (1993)
  5. Yarchoan R, "Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders. A progress report", N Engl J Med, 316, pp.557~564 (1987)
  6. Broder S, "The development of antiretroviral therapy and its impact on the HIV-1", AIDS pandemic, 2010, pp.85, 1~18
  7. Wilen CB, "HIV: cell binding and entry", Cold Spring Harb Perspect Med, 2, pp.a006866~ (2012)
  8. Laskey SB, "A mechanistic theory to explain the efficacy of antiretroviral therapy", Nat Rev Microbiol, 12, pp.772~780 (2014)
  9. Cihlar T, "Current status and prospects of HIV treatment", Curr Opin Virol, 18, pp.50~56 (2016)
  10. Arts EJ, "HIV-1 antiretroviral drug therapy", Cold Spring Harb Perspect Med, 2, pp.a007161~ (2012)
  11. Mitsuya H, "3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III", lymphadenopathy-associated virus in vitro, 1985, pp.82, 7096~7100
  12. Namasivayam V, "The journey of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) from lab to clinic", J Med Chem, 62, pp.4851~4883 (2019)
  13. De Clercq E, "Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future", Chem Biodivers, 1, pp.44~64 (2004)
  14. De Clercq E, "Approved antiviral drugs over the past 50 years", Clin Microbiol Rev, 29, pp.695~747 (2016)
  15. Wassner C, "A Review and clinical understanding of tenofovir: tenofovir disoproxil fumarate versus tenofovir alafenamide", J Int Assoc Provid AIDS Care, 19, pp.2325958220919231~ (2020)
  16. Wang Y, "Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment", Expert Opin Drug Metab Toxicol, 15, pp.813~829 (2019)
  17. Ghosh AK, "Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV", AIDS, 2016, pp.59, 5172~5208
  18. Boden D, "Resistance to human immunodeficiency virus type 1 protease inhibitors", Antimicrob Agents Chemother, 42, pp.2775~2783 (1998)
  19. Davis DA, "Activity of human immunodeficiency virus type 1 protease inhibitors against the initial autocleavage in Gag-Pol polyprotein processing", Antimicrob Agents Chemother, 56, pp.3620~3628 (2012)
  20. Patick AK, "Protease inhibitors as antiviral agents", Clin Microbiol Rev, 11, pp.614~627 (1998)
  21. Ali A, "Molecular basis for drug resistance in HIV-1 protease", Viruses, 2, pp.2509~2535 (2010)
  22. da Cunha J, "Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs", World J Virol, 4, pp.56~77 (2015)
  23. Zhuang M, "Trimeric, coiled-coil extension on peptide fusion inhibitor of HIV-1 influences selection of resistance pathways", J Biol Chem, 287, pp.8297~8309 (2012)
  24. Wang W, "Selection with a peptide fusion inhibitor corresponding to the first heptad repeat of HIV-1 gp41 identifies two genetic pathways conferring crossresistance to peptide fusion inhibitors corresponding to the first and second heptad repeats (HR1 and HR2) of gp41", J Virol, 85, pp.12929~12938 (2011)
  25. Lalezari JP, "Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America", N Engl J Med, 348, pp.2175~2185 (2003)
  26. Kitchen CM, "Enfuvirtide antiretroviral therapy in HIV-1 infection", Ther Clin Risk Manag, 4, pp.433~439 (2008)
  27. Huet T, "Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity", Antimicrob Agents Chemother, 54, pp.134~142 (2010)
  28. Woollard SM, "Maraviroc: a review of its use in HIV infection and beyond", Drug Des Devel Ther, 9, pp.5447~5468 (2015)
  29. Van Der Ryst E, "Maraviroc - A CCR5 antagonist for the treatment of HIV-1 infection", Front Immunol, 6, pp.277~ (2015)
  30. Qian K, "HIV entry inhibitors and their potential in HIV therapy", Med Res Rev, 29, pp.369~393 (2009)
  31. Shi S, "Development of peptide inhibitors of HIV transmission", Bioact Mater, 1, pp.109~121 (2016)
  32. Kondru R, "Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists", Mol Pharmacol, 73, pp.789~800 (2008)
  33. Dorr P, "Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity", Antimicrob Agents Chemother, 49, pp.4721~4732 (2005)
  34. Craigie R, "HIV DNA integration", Cold Spring Harb Perspect Med, 2, pp.a006890~ (2012)
  35. Hindmarsh P, "Retroviral DNA integration", Microbiol Mol Biol Rev, 63, pp.836~843 (1999)
  36. Engelman A, "Retroviral integrase structure and DNA recombination mechanism", Microbiol Spectr, 2, pp.1~22 (2014)
  37. Lee GE, "Structural insights on retroviral DNA integration: learning from foamy viruses", Viruses, 11, pp.770~ (2019)
  38. Mesplède T, "Integrase strand transfer inhibitors in HIV therapy", Infect Dis Ther, 2, pp.83~93 (2013)
  39. Wong E, "HIV pharmacotherapy: A review of integrase inhibitors", JAAPA, 2, pp.36~40 (2016)
  40. Blanco JL, "HIV integrase inhibitors: a new era in the treatment of HIV", Expert Opin Pharmacother, 16, pp.1313~1324 (2015)
  41. Hare S, "Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance", Proc Natl Acad Sci U S A, 107, pp.20057~20062 (2010)
  42. Engelman AN, "Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition", J Biol Chem, 294, pp.15137~15157 (2019)
  43. Choi E, "Recent advances in the discovery of small-molecule inhibitors of HIV-1 integrase", Future Sci OA, 4, pp.FSO338~ (2018)
  44. Deeks ED, "Bictegravir", emtricitabine, Drugs, pp.2018, 78[DOI]
  45. Venter WDF, "Dolutegravir plus two different prodrugs of tenofovir to treat HIV", N Engl J Med, 381, pp.803~815 (2019)
  46. Radford M, "Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients", AIDS, 33, pp.1739~1749 (2019)
  47. Oliveira M, "Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir", Retrovirology, 15, pp.56~ (2018)
  48. Sax PE, "Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial", Lancet, 390, pp.2073~2082 (2017)
  49. Hill L, "Profile of bictegravir", emtricitabine, HIV AIDS (Auckl), pp.2018, 10[DOI]
  50. Xu L, "Cobicistat (GS-9350): A potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer", ACS Med Chem Lett, 1, pp.209~213 (2010)
  51. Shah BM, "Cobicistat: a new boost for the treatment of human immunodeficiency virus infection", Pharmacotherapy, 33, pp.1107~1116 (2013)
  52. Crutchley RD, "Evaluating the role of atazanavir", cobicistat and darunavir, HIV AIDS (Auckl), pp.2016, 8[DOI]
  53. Temesgen Z, "Cobicistat, a pharmacoenhancer for HIV treatments", Drugs Today (Barc), 49, pp.233~237 (2013)
  54. von Hentig N, "Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapy", HIV AIDS (Auckl), 8, pp.1~16 (2015)
  55. Lepist EI, "Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro", Antimicrob Agents Chemother, 56, pp.5409~5413 (2012)
  56. Deeks ED, "Darunavir", cobicistat, tenofovir Alafenamide: A review in HIV-1 infection, pp.Drugs, 2018[DOI]
  57. Fernandez C, "Evaluating cabotegravir", rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential, 2019, pp.11, 179~192
  58. Trezza C, "Formulation and pharmacology of long-acting cabotegravir", Curr Opin HIV AIDS, 10, pp.239~245 (2015)
  59. Whitfield T, "Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date", HIV AIDS (Auckl), 8, pp.157~164 (2016)
  60. Usach I, "Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability", J Int AIDS Soc, 16, pp.1~14 (2013)
  61. Swindells S, "Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression", N Engl J Med, 382, pp.1112~1123 (2020)
  62. Landovitz RJ, "The promise and pitfalls of long-acting injectable agents for HIV prevention", Curr Opin HIV AIDS, 11, pp.122~128 (2016)
  63. Singh K, "Long-acting anti-HIV drugs targeting HIV-1 reverse transcriptase and integrase", Pharmaceuticals (Basel), 12, pp.62~ (2019)
  64. Margolis DA, "Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority tria", Lancet, 390, pp.1499~1510 (2017)
  65. Pham HT, "Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection", Drugs Context, 9 (2020)
  66. Gatell JM, "Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF", FTC in ART-naive HIV-positive patients, 2014, pp.1(4 Suppl 3), 19532~
  67. Molina JM, "Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial", Lancet HIV, 5, pp.e211~e220 (2018)
  68. Colombier MA, "Doravirine: a review", Curr Opin HIV AIDS, 13, pp.308~314 (2018)
  69. Wilby KJ, "Clinical pharmacokinetics and drug interactions of doravirine", Eur J Drug Metab Pharmacokinet, 43, pp.637~644 (2018)
  70. Cahn P, "Fostemsavir: a new CD4 attachment inhibitor", Curr Opin HIV AIDS, 13, pp.341~345 (2018)
  71. Kozal M, "Fostemsavir in adults with multidrug-resistant HIV-1 infection", N Engl J Med, 382, pp.1232~1243 (2020)
  72. Chen K, "Synthesis of the 6-azaindole containing HIV-1 attachment inhibitor pro-drug, BMS-663068", J Org Chem, 79, pp.8757~8767 (2014)
  73. Lalezari J, "Safety profile of HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviralexperienced subjects: week 24 analysis", J Int AIDS Soc, 17(4 Suppl 3), pp.19530~ (2014)
  74. Iacob SA, "Ibalizumab targeting CD4 receptors, an emerging molecule in HIV therapy", Front Microbiol, 8, pp.2323~ (2017)
  75. Beccari MV, "Ibalizumab, a novel monoclonal antibody for the management of multidrug-resistant HIV-1 infection", Antimicrob Agents Chemother, 63, pp.e00110~e00119 (2019)
  76. Blair HA, "Ibalizumab: A review in multidrug-resistant HIV-1 infection", Drugs, 80, pp.189~196 (2020)
  77. Emu B, "Phase 3Study of Ibalizumab for Multidrug-Resistant HIV-1", N Engl J Med, 379, pp.645~654 (2018)
  78. Rizza SA, "Ibalizumab for the treatment of multidrug-resistant HIV-1infection", Drugs Today (Barc), 55, pp.25~34 (2019)
  79. Michailidis E, "4′-Ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms", J Biol Chem, 289, pp.24533~24548 (2014)
  80. "HIV pipeline 2020: new drugs in development"[URL]
  81. Link JO, "Clinical targeting of HIV capsid protein with a long-acting small molecule", Nature, 584, pp.614~618 (2020)
  82. Bester SM, "Structural and mechanistic bases for a potent HIV-1 capsid inhibitor", Science, 370, pp.360~364 (2020)
  83. Ott M, "The control of HIV transcription: keeping RNA polymerase II on track", Cell Host Microbe, 10, pp.426~435 (2011)
  84. Mousseau G, "Strategies to block HIV transcription: Focus on small molecule tat inhibitors", Biology (Basel), 1, pp.668~697 (2012)
  85. Shin Y, "Development of a dual reporter screening assay for distinguishing the inhibition of HIV Tat-mediated transcription from off-target effects", J Virol Methods, 249, pp.1~9 (2017)
  86. Shin Y, "Identification of novel compounds against Tat-mediated human immunodeficiency virus-1 transcription by high-throughput functional screening assay", Biochem Biophys Res Commun, 523, pp.368~374 (2020)
  87. Huang H, "Structure of a covalently trapped catalytic complex of HIV-1reverse transcriptase: implications for drug resistance", Science, 282, pp.1669~1675 (1998)
  88. Lansdon EB, "Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design", J Med Chem, 53, pp.4295~4299 (2010)
  89. King NM, "Extreme entropy-enthalpy compensation in a drug-resistant variant of HIV-1 protease", ACS Chem Biol, 7, pp.1536~1546 (2012)
  90. Berkhout B, "Is there a future for antiviral fusion inhibitors?", Curr Opin Virol, 2, pp.50~59 (2012)
  91. Haqqani AA, "Entry inhibitors and their use in the treatment of HIV-1 infection", Antiviral Res, 98, pp.158~170 (2013)

관련 논문AI추천

Long-Acting Injectable Antiretroviral Agents for HIV Treatment and Prevention김연숙대한감염학회 · Infection and Chemotherapy2021 · 제53권 제4호Advancements in Antiviral Drug Development: Comprehensive Insights into Design Strategies and Mechanisms Targeting Key Viral ProteinsCheng Wang, Hangyu Wang, Hongyan Wang, Jie Shen, Kangning Han, Linmiao Wei, Panpan Li, Shuai Wang, Yichen Shi한국미생물·생명공학회 · Journal of Microbiology and Biotechnology2024 · 제34권 제7호Identification of a novel type of small molecule inhibitor against HIV-1김민정, 김병수, 김선희, 박정애, 유경리, 유지창생화학분자생물학회 · BMB Reports2015 · 제48권 제2호Safety and Effectiveness of Darunavir in Korean Patients with Human Immunodeficiency Virus 1 Infection: A Post-Marketing Observational StudyKang Jiho, Kim Hyeongyeong, Kim Youngdoe대한감염학회 · Infection and Chemotherapy2021 · 제53권 제3호COVID-19 Antiviral and Treatment Candidates: Current Status김다정, 김정기, 김지연, 박성규, Españo Erica대한면역학회 · Immune Network2021 · 제21권 제1호Comparison of Antiretroviral Regimens: Adverse Effects and Tolerability Failure that Cause Regimen Switching진선, 김민정, 김수정, 김신우, 김연주, 박정화, 이종명, 장현하, 정혜진대한감염학회 · Infection and Chemotherapy2015 · 제47권 제4호

이 간행물의 다른 논문 (17건)

Effectiveness of Mavrilimumab in Viral Infections Including SARS-CoV-2 Infection - A Brief ReviewNasir Hassan, Kumari Priyanka, Lathiya Maulik, Michel George, Pandya Naushira, Halpern John, Sanchez-Gonzalez Marcos A., Offor Rita, Nwankwo Kanayo, Arif Uroosa, Waheed Khurram, Bhatt Kinal, Garimella Radhika, Taugir Rahima, Mehta Isha, Jamal Muhammad, Vijayan Rupalakshmipp. 1-12Comparison of Comorbidities in Relation to Critical Conditions among Coronavirus Disease 2019 Patients: A Network Meta-AnalysisHoang Tung, Tran Thi Anh Thopp. 13-28Etiology, Characteristics, and Outcomes of Community-Onset Pyomyositis in Korea: A Multicenter StudyHong Hyo-Lim, 최성호, 최상호, 정지원, 조오현, Kim Min-Chul, Kwak Yee Gyung, Park Se Yoon, 김탁, Park Seong Yeon, Yu Shi Nae, Kim Yong Kyun, Song Eun Hee, Park Ki-Ho, The Korean SSTI Study Grouppp. 46-52Machine-Learning-Based Approach to Differential Diagnosis in Tuberculous and Viral MeningitisJeon Min Huok, Park Ki-Ho, 정영섭, Kim Min-Chul, Kim Sung-Han, 최승임, Park Joung Ha, Lee Yu-Mi, Lee Eunyoung, Choo Eun Ju, Kim Tae Hyong, Jeon Minjun, Kim Tark, Park Se Yoon, Lee Mi Suk, Park Seong Yeonpp. 53-62The Impact of Modifying Empirical Antibiotic Therapy Based on Intestinal Colonization Status on Clinical Outcomes of Febrile Neutropenic PatientsAlrstom Ali, Alsuliman Tamim, Daher Nizar, Abouharb Raedpp. 63-74
원문 보기